COPD Clinical Trial
— COPD-HIIT-ACOfficial title:
Feasibility and Acute Effects of Supramaximal High-Intensity Interval Training in People With COPD
Verified date | June 2023 |
Source | Umeå University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
High-intensity exercise is essential for optimal development of cardiorespiratory fitness and health. This is, however, challenging for most people with chronic obstructive pulmonary disease (COPD) due to ventilatory limitations, leading to exercise at lower intensities accompanied by suboptimal stress on the cardiovascular and muscular system. The aims of this cross-over trial is: 1. To compare the acute effects of short-duration supramaximal high-intensity interval training (HIIT) vs. traditional moderate-intensity continuous training (MICT) in people with COPD and matched healthy controls (HC). 2. To investigate the feasibility of supramaximal HIIT in people with COPD and matched HC. 3. To compare the cardiorespiratory demand, exercise intensity and symptoms during a modified Borg Cycle Strength Test (BCST) and a cardiopulmonary exercise test (CPET) in people with COPD and HC.
Status | Completed |
Enrollment | 32 |
Est. completion date | December 22, 2022 |
Est. primary completion date | December 22, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years and older |
Eligibility | COPD Inclusion Criteria: - COPD with non-reversible airflow obstruction diagnosis (post-bronchodilator forced expiratory volume during the first second/forced vital capacity (FEV1/FVC) < 0.7) - Age: > 40 years Exclusion Criteria: - Recent exacerbation of COPD (< 6 weeks) - Neuromuscular, orthopaedic and/or any other condition that can compromise participation in testing - Recent lung cancer (< 5 years) - Unstable cardiac disease and/or cardiac stimulator HC Inclusion Criteria: - Age: > 40 years Exclusion Criteria: - Neuromuscular, orthopaedic and/or any other condition that can compromise participation in testing - Any respiratory disease - Recent lung cancer (< 5 years) - Unstable cardiac disease and/or cardiac stimulator - Too low or high physical activity level that prohibits matching |
Country | Name | City | State |
---|---|---|---|
Sweden | Umeå University | Umeå |
Lead Sponsor | Collaborator |
---|---|
Umeå University | Riksförbundet HjärtLung, Swedish Heart Lung Foundation, The Swedish Research Council |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Exercise intensity | Produced watt at the set training intensity | During visit 2 (week 1) | |
Primary | Exercise intensity | Produced watt at the set training intensity | During visit 3 (week 2) | |
Primary | Exercise intensity | Produced watt at the set training intensity | During visit 4 (week 2) | |
Primary | Brain-derived neurotrophic factor (BDNF) | Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL. | During visit 2 (week 1) | |
Primary | Brain-derived neurotrophic factor (BDNF) | Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL. | During visit 3 (week 2) | |
Primary | Brain-derived neurotrophic factor (BDNF) | Concentration of BDNF in obtained venous blood samples before, during and after exercise. Measured as ng/mL or pg/mL. | During visit 4 (week 2) | |
Secondary | Cardiorespiratory demand | Gas exchange parameters (e.g. VO2, VCO2, ventilatory equivalents, RER) and lung volumes (e.g. VE, Vt, breathing frequency) obtained with a metabolic cart (breath by breath methodology) and heart rate (beats per minutes) during exercise during exercise. | During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) | |
Secondary | Venous blood lactate concentration | Measured before, during and after exercise. | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) | |
Secondary | Rating of perceived exertion | Rating of perceived exertion scale (Borg RPE). Minimum value = 6 Maximum value = 20 A higher score means higher exertion. | During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) | |
Secondary | Rating of symptoms | Rating of dyspnea and leg fatigue symptoms via Borg CR (category ratio) 10 during exercise Minimum value = 0 Maximum value = 10 A higher score means higher severity of symptoms | During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) | |
Secondary | Peripheral blood oxygen saturation (SpO2) | SpO2 during exercise | During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) | |
Secondary | Blood pressure | Systolic and diastolic blood pressure during exercise | During visit 1 (CPET and BCST; week 1), visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) | |
Secondary | Circulating levels of neurotrophic factors | Plasma or serum concentration (measured as mg/l, ng/l, or pq/l) of irisin, cathepsin B, clusterin, in obtained venous blood samples before, during and after exercise. | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) | |
Secondary | Circulating levels of exerkines | Plasma or serum concentration of interleukin (IL)-1b, IL-4, IL-6, IL-8, IL-10, IL-13, IL-15, IL-17, tumor necrosis factor (TNF)-a, vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and adiponectin in obtained venous blood samples before, during and after exercise. | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) | |
Secondary | Exercise session completion | Number of uninterrupted exercise sessions | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) | |
Secondary | Exercise preference | Preference for HIIT at 60% of MPO6 or MICT, defined as answer on the following question:
"If the MICT and HIIT would be equally effective in improving your health and physical capacity, which one would you prefer to perform?" |
At the end of visit 3 (week 2) | |
Secondary | Session RPE | Rating of session RPE on Borg CR (category ratio) 10 is assessed 30 min after every exercise session Minimum value = 0 Maximum value = 10 A higher score means higher session exertion | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) | |
Secondary | Exercise capacity | Maximal aerobic power (MAP) expressed as produced watt at VO2peak | During visit 1 (CPET; week 1) | |
Secondary | Exercise intensity | Maximum mean power output for 30 seconds (MPO30) in watts | During visit 1 (BCST; week 1) | |
Secondary | Adverse events | Occurence and severity of adverse events. The severity of adverse events will be assessed and rated into four different categories: 1) minor and temporary, 2) serious symptoms (potential risk of severe injury or life threatening, 3) manifest injury or disease and 4) death. An adverse event rate will be calculated for each participant as the total number of sessions during which any adverse events occurred divided by the total number of attended sessions. | During visit 2 (week 1), visit 3 (week 2) and visit 4 (week 2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06000696 -
Healthy at Home Pilot
|
||
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04105075 -
COPD in Obese Patients
|
||
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Active, not recruiting |
NCT04075331 -
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
|
Phase 2/Phase 3 | |
Terminated |
NCT03640260 -
Respiratory Regulation With Biofeedback in COPD
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|
||
Withdrawn |
NCT04210050 -
Sleep Ventilation for Patients With Advanced Hypercapnic COPD
|
N/A | |
Terminated |
NCT03284203 -
Feasibility of At-Home Handheld Spirometry
|
N/A | |
Recruiting |
NCT06110403 -
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06040424 -
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
Completed |
NCT04485741 -
Strados System at Center of Excellence
|
||
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A |